NEWS IN BRIEF

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

By Flora Southey contact

- Last updated on GMT

WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China
WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China

Related tags: Wuxi biologics, China, CDMO

Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.

Contract development and manufacturing organisation (CDMO) WuXi Biologics announced last week it has broken ground on its Biologics Manufacturing Center of Excellence (MFG8) in Northern China’s Hebei province.

The $240m (€203m) facility will house process development labs, 5,000L bioreactor capacity for clinical manufacturing, and 48,000L bioreactor capacity for commercial manufacturing.

According to the firm, the plant will serve both Chinese and global clients, and be built to meet current good manufacturing practice (cGMP) standards of the US, the European Union, and China. Operations are expected to begin in 2020.

“We are pleased to break ground today and look forward to the operations of this new Biologics Center,” ​said Chris Chen in a statement.

“This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners, and ultimately to benefit patients worldwide,” ​he added.

Related news

Show more

Related products

show more

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us

Products

View more

Webinars